

Mydekla 60mg Tablet (daclatasvir dihydrochloride(60))
Manufactured By
Mylan pharmaceuticals pvt ltd
Pack Of
28
Salt Composition
daclatasvir dihydrochloride(60)
Storage
Keep in cold place
Overview
Mydekla 60mg Tablet is an antiviral medication that is used in treatment of chronic hepatitis C virus (HCV) infection. The medicine active composition is daclatasvir dihydrochloride in 60mg concentration. It belongs to the drug class of Direct-Acting Antiviral (DAA) that works by blocking a viral protein (NS5A) required for the hepatitis C virus to multiply.
This reduces the amount of virus in the body and helps clear the infection overtime. Use the medicine exactly as prescribed by the healthcare professional to ensure safe treatment.
Quick Product Facts
| Field | Publication wording |
|---|---|
| Brand | mydekla |
| Generic / Active Ingredient | Daclatasvir |
| Strength | 60 |
| Dosage Form | Tablet |
| Manufacturer / Marketer | mylan pharmaceuticals pvt ltd |
| Pack Size | 28 |
| Prescription Required | Yes |
| Therapeutic Categories | Hepatitis Medicines |
| Uses | hepatitis |
Uses and Indications
Hepatitis C
Side Effects of Mydekla 60mg Tablet
Most of the medicine cause side effects, some are acute and some are mild. Consult the healthcare professional if any of these symptoms persist while using daclatasvir dihydrochloride 60 mg tablet.
● Nausea
● Headache
● Tiredness
● Dizziness
● Decreased heart rate
● Liver failure
● Reactivation of hepatitis B virus
Mydekla 60mg Tablet Dosage and How To Take It
Daclatasvir Dihydrochloride 60mg Tablet should be taken at the fixed time everyday with or without food for better absorption. Always consult a healthcare professional to ensure safe and effective treatment option.
Proper intake may help achieve maximum viral suppression, improve treatment success rate and reduce the risk of drug resistance in patients with hepatitis C.
Safety Advice for Mydekla 60mg Tablet
- • Alcohol: Alcohol should be avoiding while using Mydekla 60mg Tablet as it can disrupt the treatment.
- • Driving: Mydekla 60mg Tablet may cause drowsiness or sleepiness in some individuals, which can affect alertness and concentration. Therefore, avoid driving while using the medicine.
- • Pregnancy: Mydekla 60mg Tablet (Daclatasvir Dihydrochloride) is not recommended for pregnant women, as it harms the developing fetus and can cause serious birth defects or complications.
- • Breast feeding: Daclatasvir Dihydrochloride 60mg Tablet is not prescribed for breastfeeding women, as the medicine is directly passes from mother’s blood stream into breast milk which may harm the nursing infant.
- • Kidney: Patient with kidney disease, should consult a healthcare professional before using Mydekla 60mg Tablet to ensure safe treatment.
- • Liver: Mydekla 60mg Tablet (Daclatasvir Dihydrochloride) should not be taken by liver patient because it can put extra strain on the liver and may worsen liver function.
FAQs About Mydekla 60mg Tablet
What is Daclatasvir Dihydrochloride 60mg Tablet dosage and duration?
Daclatasvir Dihydrochloride 60mg Tablet should be taken once a day, consult the doctor about the proper administration of the drug.
Who can use Mydekla 60mg Tablet?
Mydekla 60mg Tablet is used by the patient of chronic hepatitis C infection, as prescribed by the healthcare professional.
Can I use Daclatasvir Dihydrochloride 60mg Tablet with other combination of treatment?
Daclatasvir Dihydrochloride 60mg Tablet can be used alongside with other treatments, but only under the supervision of a healthcare professional.
Is Daclatasvir Dihydrochloride 60mg Tablet completely curing the chronic hepatitis C infection?
Daclatasvir Dihydrochloride 60mg Tablet reduce the growth of virus in the body and give patient relief but it does not offer a permanent cure and must be taken as a long term treatment plan under medical supervision.
What are the side effects of Daclatasvir Dihydrochloride 60mg Tablet?
The common side effects of Daclatasvir Dihydrochloride 60mg Tablet is nausea, headache, tiredness etc. Reach out to the doctor if any of the symptoms persist or worsen.
References
● Reviriego, C. (2011). Daclatasvir dihydrochloride. Drugs of the Future, 36(10).
● Hassib, S. T., Taha, E. A., Elkady, E. F., & Barakat, G. H. (2017). Reversed-phase liquid chromatographic method for determination of daclatasvir dihydrochloride and study of its degradation behavior. Chromatographia, 80(7), 1101-1107.
● Shah, S. H., Nasiri, M. I., Sarwar, H., Ali, A., Naqvi, S. B. S., Anwer, S., & Kashif, M. (2021). RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form. Pak. J. Pharm. Sci, 34(3), 951-956.
● Abdel-Lateef, M. A., Omar, M. A., Ali, R., & Derayea, S. M. (2019). Xanthene based spectroscopic probe for the analysis of HCV antiviral, daclatasvir dihydrochloride, through feasible complexation reaction. Microchemical Journal, 145, 672-675.
● El Azab, N. F., El-Mosallamy, S. S., Mahmoud, A. M., & Trabik, Y. A. (2025). Design of a core-shell molecularly imprinted polymer for highly selective detection of daclatasvir dihydrochloride in tablets and human plasma. Microchemical Journal, 213, 113723.
Marketer Details
Mylan pharmaceuticals pvt ltd
Disclaimer
Globanspharma main goal is to ensure that its consumers get correct, authentic, and reliable information that has been examined by medical professionals. This website's content has only been created for informational purposes. However, this is not meant to replace the medical advice and treatment given by a qualified physician. The information presented herein may not cover everything about particular lab tests, medicines, and health conditions, all possible side effects, and warnings. Please discuss all your queries related to any medication and illness with your doctor. We intend to support and maintain the doctor-patient relationship, not to substitute it or take its place.


